Healthcare

DenovoMatrix binds funding
TU Dresden spinout DenovoMatrix hopes to commercialise a method for effectively cultivating stem cell production.
Sensorygen bites into $50,000
Vertical Venture Partners has joined university venture fund Highlander Venture Fund as an investor in UC Riverside-founded mosquito repellent developer Sensorygen.
Mission Bio identifies $30m series B
Agilent and Lam Research participated in a $30m series B for UCSF's DNA analysis spinout Mission Bio, whose existing shareholders include Stanford-StartX Fund.
Moderna loads up $604m in IPO
Investors including co-founder and Harvard professor Timothy Springer scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
UCL eyes $126m second fund
University College London hopes to generate as much as $126m for its second Technology Fund, with British Business Bank thought to be among potential limited partners.
Istesso stakes $7.6m
IP Group has poured more funding into Istesso, whose treatment for rheumatoid arthritis traces its roots to an Aberdeen spinout, to drive immuno-metabolism therapies for autoimmune diseases.
Uniseed sends Cardihab $1.4m
Uniseed has returned to back Csiro digital health spinout Cardihab after an earlier round which also raised $1.4m in 2017.
10X Genomics picks up Spatial Transcriptomics
10X Genomics has purchased genomic analysis platform Spatial Transcriptomics, based on research at Karolinska Institute and KTH Royal Institute of Technology.

Other News

Lund launches Asgard Therapeutics
Asgard Therapeutics will develop cancer therapies which use reprogrammed human skin cells to improve the immune system’s capacity to identify cancerous particles.
Genomics encounters $42m series B
Foresite Capital and F-Prime Capital joined earlier series B investors including Oxford Science Innovations to take Oxford drug discovery spinout Genomics’ total funding to $58.2m.
Evox visits Gates Foundation for funding
Oxford drug delivery spinout Evox Therapeutics collected funding from Bill and Melinda Gates Foundation in its bid to engineer exosome delivery vessels for a range of drugs.
Bios signals for $4.5m
Cambridge neural interface spinout Bios will use some of the seed capital to develop an interface between prosthetic objects and the human nervous system.
Minnesota spawns Vascudyne
Vascudyne will develop vascular medical devices offering enhanced performance on the back of a stem cell-grown tissue with similar biological and mechanical qualities to the native equivalent.
Igem sets $6.4m in stone
The KCL immuno-oncology spinout’s second series A close included investment from UCL Technology Fund, Alsa Holding and Epidarex Capital.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Big deal: Roche derives MS treatment
Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.
test reg

Login